91O - Quality of life (QoL) analysis from ENSURE, a phase 3, open-label study of first-line erlotinib versus gemcitabine/cisplatin (gp) in Asian patients...

Date 27 March 2014
Event ELCC 2014
Session Proffered Papers 1 - Advanced disease with tageted agents
Topics Anti-Cancer Agents & Biologic Therapy
Supportive Care
Non-Small-Cell Lung Cancer, Metastatic
Presenter Yi-Long Wu
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors Y. Wu1, C. Zhou2, G. Wu3, X. Liu4, Z. Zhong5, S. Lu6, M.C.L. Fernando7, C. Liam8, M. Chen9, Y. Zuo10
  • 1Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN
  • 2Department Of Oncology, Affiliated Shanghai Pulmonary Hospital of Tongji University, Shanghai/CN
  • 3Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan/CN
  • 4Department Of Lung Cancer, 307 Hospital of PLA, Beijing/CN
  • 5Cancer Centre, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing/CN
  • 6Shanghai Lung Cancer Center, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai/CN
  • 7Internal Medicine, Manila Doctors Hospital, Manila/PH
  • 8Department Of Medicine, University of Malaya, Kuala Lumpur/MY
  • 9Biostatistics, Roche Product Development in Asia Pacific, Shanghai/CN
  • 10Clinical Scientist, Roche Product Development in Asia Pacific, Shanghai/CN


ENSURE, a randomised, phase 3 study, met its primary endpoint of improved progression-free survival (PFS) with erlotinib vs GP in Asian patients with EGFR mut+ NSCLC: interim analysis median PFS 11.0 vs 5.5 months (HR 0.34, 95% CI 0.22–0.51; p<0.0001); updated analysis median PFS 11.0 vs 5.5 months (HR 0.33, 95% CI 0.23–0.47). QoL is important in assessing treatment benefit, as it examines the balance between efficacy and tolerability. Here we present QoL data from ENSURE (updated data cut-off).